The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A., Leibowitz-Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 2,829
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A., & Albain, K. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912303412706 · Cited by 2,174
Zahorec, R. (2001) · Bratislava Medical Journal · doi:10.1007/bf03656390 · Cited by 1,601
The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
Guthrie, G. J. K., Charles, K. A., Roxburgh, C. S. D., Horgan, P. G., McMillan, D. C., & Clarke, S. J. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.03.010 · Cited by 1,552
Sperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., Sneed, P. K., Chao, S. T., Weil, R. J., Suh, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0527 · Cited by 1,425
Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064
Pseudoprogression and Immune-Related Response in Solid Tumors
Chiou, V. L., & Burotto, M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6870 · Cited by 903
Metastatic sites and survival in lung cancer
Riihimäki, M., Hemminki, A., Fallah, M., Thomsen, H., Sundquist, K., Sundquist, J., & Hemminki, K. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.07.020 · Cited by 888
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589
Ferrucci, P. F., Gandini, S., Battaglia, A., Alfieri, S., Di Giacomo, A. M., Giannarelli, D., Cappellini, G. C. A., De Galitiis, F., Marchetti, P., Amato, G., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.180 · Cited by 262
The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer
Kang, M. H., Go, S.-I., Song, H.-N., Lee, A., Kim, S.-H., Kang, J.-H., Jeong, B.-K., Kang, K. M., Ling, H., & Lee, G.-W. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.317 · Cited by 199
Cannon, N. A., Meyer, J., Iyengar, P., Ahn, C., Westover, K. D., Choy, H., & Timmerman, R. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000399 · Cited by 194
Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
Korpanty, G. J., Graham, D. M., Vincent, M. D., & Leighl, N. B. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00204 · Cited by 175
Ascierto, P. A., Simeone, E., Sileni, V., Pigozzo, J., Maio, M., Altomonte, M., Del Vecchio, M., Di Guardo, L., Marchetti, P., Ridolfi, R., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-116 · Cited by 163
van Soest, R. J., Templeton, A. J., Vera-Badillo, F., Mercier, F., Sonpavde, G., Amir, E., TOMBAL, B. F., Rosenthal, M. A., Eisenberger, M. A., Tannock, I. F., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu569 · Cited by 147
Giacomo, A. M. D., Ascierto, P. A., Queirolo, P., Pilla, L., Ridolfi, R., Santinami, M., Testori, A., Simeone, E., Guidoboni, M., Maurichi, A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu577 · Cited by 140
Bowyer, S. E., Prithviraj, P., Lorigan, P. C., Larkin, J., McArthur, G. A., Atkinson, V. G., Millward, M., Khou, M., Diem, S., Ramanujam, S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.107 · Cited by 139
Comparative Effectiveness Research in Oncology Methodology: Observational Data
Hershman, D. L., & Wright, J. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6701 · Cited by 132
Ahmad, S. S., Qian, W., Ellis, S. G., Mason, E. F., Khattak, M. A., Gupta, A., Shaw, H. M., Quinton, A., Kovarikova, J., Thillai, K., et al. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000185 · Cited by 53
Randomized Clinical Trials and Observational Studies: Is There a Battle?
Chávez‐MacGregor, M., & Giordano, S. H. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.7487 · Cited by 52
Jung, M., Lee, J., Kim, T. M., Lee, D. H., Kang, J., Oh, S. Y., Lee, S. J., & Shin, S. J. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2016.024 · Cited by 35
A framework for understanding cancer comparative effectiveness research data needs
Carpenter, W. R., Meyer, A., Abernethy, A. P., Stürmer, T., & Kosorok, M. R. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.06.005 · Cited by 34
Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma
Khoja, L., Atenafu, E. G., Ye, Q., Gedye, C. A., Chappell, M., Hogg, D., Butler, M. O., & Joshua, A. M. (2015) · Oncology Letters · doi:10.3892/ol.2015.4069 · Cited by 34
Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab
Shreders, A. J., Joseph, R. W., Peng, C., Ye, F., Zhao, S., Puzanov, I. J., Sosman, J. A., & Johnson, D. B. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0281 · Cited by 21
Cited by
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Neutrophil diversity and plasticity in tumour progression and therapy
Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., & Mantovani, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0281-y · Cited by 1,285
Diem, S., Schmid, S., Krapf, M., Flatz, L., Born, D., Jochum, W., Templeton, A. J., & Früh, M. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.024 · Cited by 986
Mezquita, L., Auclin, E., Ferrara, R., Charrier, M., Remon, J., Planchard, D., Ponce, S., Ares, L. P., Leroy, L., Audigier-Valette, C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4771 · Cited by 913
Heinhuis, K. M., Ros, W., Kok, M., Steeghs, N., Beijnen, J. H., & Schellens, J. H. M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy551 · Cited by 557
Metadata
- Authors
- Bagley, S. J., Kothari, S., Aggarwal, C., Bauml, J. M., Alley, E. W., Evans, T. L., Kosteva, J. A., Ciunci, C. A., Gabriel, P. E., Thompson, J. C., Stonehouse-Lee, S., Sherry, V. E., Gilbert, E., Eaby-Sandy, B., Mutale, F., DiLullo, G., Cohen, R. B., Vachani, A., & Langer, C. J.
- Venue
- Lung Cancer
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 106
- Pages
- 1-7
- ISSN
- 0169-5002 (ISSN-L)
- OpenAlex
- W2581283430
- Cited by
- 511
- References
- 31
- FWCI
- 24.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.